Compare Davita Inc (DVA) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs W W Grainger Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.38B), while W W Grainger Inc trades at $1,300.82 (market cap $61.32B). The key difference: W W Grainger Inc is far larger — about 5.4× Davita Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | GWW | |
|---|---|---|
Market Cap | $11.38B | $61.32B |
Sector | Health | Technology |
52-Week High | $240.96 | $1.40K |
52-Week Low | $103.87 | $918.18 |
Enterprise Value | $24.10B | $63.53B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GWW trades at $1,277.55, down 0.39% on the day, amid a bearish technical signal. The stock has shown strong fundamental performance with Q2 2026 EPS beating estimates at $12.01 and revenue growth to $5.0 billion, leading to a raised full-year outlook. Analyst consensus is a Buy with a $1,310 price target, though technical indicators suggest near-term pressure with support at $1,270 and resistance at $1,290.
The outlook for GWW is positive based on earnings momentum and margin expansion, but risks include macroeconomic sensitivity and competitive pressures. The stock's high P/E of 33.07 indicates premium valuation, requiring sustained growth to justify current levels. Institutional sentiment remains cautious with a Hold-heavy rating distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
